<DOC>
	<DOCNO>NCT02442180</DOCNO>
	<brief_summary>Steroid treatment choice patient severe alcoholic hepatitis . However , null- partial responder steroid treatment recommend consider liver transplantation . The yearly demand liver transplant far exceed supply available organ alcoholic liver disease controversial indication transplantation . Granulocyte-Colony Stimulating Factor ( G-CSF ) report effect proliferation hepatic progenitor alcoholic steatohepatitis . The aim study investigate efficacy G-CSF patient severe alcoholic hepatitis null partial response steroid .</brief_summary>
	<brief_title>Efficacy Safety G-CSF Patients With Severe Alcoholic Hepatitis With Null Partial Response Steroid</brief_title>
	<detailed_description>Severe alcoholic hepatitis define alcoholic hepatitis patient discriminant function ( DF ) score 32 accompany hepatic encephalopathy . These patient show poor prognosis 28 day mortality 30 50 % without treatment . Steroid ( prednisolone 40mg/day 28 day ) treatment choice patient severe alcoholic hepatitis . Alcoholic hepatitis modify DF score great equal 32 model end-stage liver disease ( MELD ) score 21 hepatic encephalopathy indication . However , null- partial responder steroid treatment recommend consider liver transplantation . The yearly demand liver transplant far exceed supply available organ alcoholic liver disease controversial indication transplantation . Even responder steroid treatment , mortality still 20 % ( 40 % without treatment 20 % steroid treatment ) . There need development new treatment catastrophic disease . Granulocyte-Colony Stimulating Factor ( G-CSF ) report effect proliferation hepatic progenitor alcoholic steatohepatitis . The aim study investigate efficacy G-CSF patient severe alcoholic hepatitis null partial response steroid .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Alcoholic</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Patients Clinical significant alcohol intake history ( men 50g within 3 month , woman 40g within 3 month ) modify DF score great equal 32 Transjugular liver biopsy show typical feature alcoholic hepatitis meet clinical diagnosis ( total serum bilirubin level 5 mg/dL , aspartate aminotransferase/alanine aminotransferase ratio &gt; 2 , aspartate aminotransferase &lt; 300 IU/L ) Included patient meet criterion Lille score &gt; 0.16 day 7 prednisolone 40mg ( 32 mg methylprednisolone ) daily treatment . Patients hepatitis B surface antigen ( HBsAg ) , antihepatitis C virus ( antiHCV ) , antihuman immunodeficiency virus ( HIV ) ( + ) Malignancy include hepatocellular carcinoma Portal vein thrombosis , hemochromatosis , autoimmune hepatitis , Wilson 's disease , alpha1antitrypsin deficiency Pregnancy , breast feeding , refuse contraception , contraception History adverse event include allergic response , hypersensitivity GCSF Hypovolemic shock due gastrointestinal hemorrhage need pack red blood cell ( RBC ) transfusion 3 unit increase modified discriminant factor ( DF ) score great equal 32 32 due gastrointestinal hemorrhage Sepsis uncontrolled acute infection Hepatic encephalopathy grade 34 History steroid pentoxifylline treatment within 3 month Myeloblast peripheral blood smear test Critical comorbidities ( type I hepatorenal syndrome , serum creatinine &gt; 2.5mg/dL , heart failure , pulmonary disease , psychiatric disease , acute pancreatitis etc . ) Who refuse participate clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>